FILE:CELG/CELG-8K-20061103181301.txt.gz
EVENTS:	Other Events	Financial Statements and Exhibits
TEXT:
ITEM: Other Events
ITEM: Financial Statements and Exhibits
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 1, 2006 CELGENE CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-16132 22-2711928 - --------------------------------- ------------------------- -------------------- (State or other jurisdiction of (Commission File Number) IRS Employer incorporation) Identification No.) 86 Morris Avenue, Summit, New Jersey 07901 - ------------------------------------------------- ------------------------- (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (908) 673-9000 --------------------------------------------------------------------- (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): [ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 8.01 OTHER EVENTS. On November 1, 2006, Celgene Corporation announced that as a result of the decision by Standard and Poor's Corporation to include Celgene Corporation in the S&P 500 Index, the Company intends to issue 15 to 20 million shares of its common stock. On November 3, 2006 Celgene Corporation announced the pricing of its public offering of 20,000,000 shares of its common stock at a public offering price of $51.60 per share with estimated proceeds of $1.032 billion. Attached hereto as Exhibits 99.1 and 99.2 are the Press Releases announcing such actions. ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS. (d) Exhibit 99.1 Press Release dated November 1, 2006 announcing Celgene Corporations's inclusion in the S&P 500 Index and intention to issue shares. Exhibit 99.2 Press Release dated November 3, 2006 announcing the pricing of Celgene Corporation's common stock public offering. SIGNATURES Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CELGENE CORPORATION Date: November 3, 2006 By: /s/ Robert J. Hugin ----------------------------- Name: Robert J. Hugin Title: President and Chief Operating Officer
EXHIBIT INDEX EXHIBIT NO. DESCRIPTION ----------- ----------- 99.1 Press Release dated November 1, 2006 announcing Celgene Corporation's inclusion in the S&P 500 Index and intention to issue 15 to 20 million shares of its common stock. 99.2 Press Release dated November 3, 2006 announcing the pricing of Celgene Corporation's public offering of 20,000,000 shares of common stock.

Exhibit 99.1 Contact: Robert J. Hugin Brian P. Gill President and COO Senior Director PR/IR Celgene Corporation Celgene Corporation (908) 673-9102 (908) 673-9530 CELGENE TO ISSUE 15 TO 20 MILLION SHARES OF COMMON STOCK SUMMIT, NJ - (NOVEMBER 1, 2006) - CELGENE CORPORATION (NASDAQ: CELG), announced that as a result of the decision by Standard and Poor's Corporation to include Celgene Corporation in the S&P 500 Index, the Company intends to issue 15 to 20 million shares of its common stock. The purpose of the offering is to partially meet the anticipated demand of index funds to purchase Celgene common stock when the Company is added to the S&P 500 Index at the close of business on Friday, November 3, 2006. Proceeds from the offering will be used for general corporate purposes, including working capital and capital expenditures, and possible acquisitions of complementary businesses, technologies or other assets. ABOUT CELGENE Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the Company's website at www.celgene.com. THIS RELEASE CONTAINS CERTAIN FORWARD-LOOKING STATEMENTS WHICH INVOLVE KNOWN AND UNKNOWN RISKS, DELAYS, UNCERTAINTIES AND OTHER FACTORS NOT UNDER THE COMPANY'S CONTROL, WHICH MAY CAUSE ACTUAL RESULTS, PERFORMANCE OR ACHIEVEMENTS OF THE COMPANY TO BE MATERIALLY DIFFERENT FROM THE RESULTS, PERFORMANCE OR OTHER EXPECTATIONS IMPLIED BY THESE FORWARD-LOOKING STATEMENTS. THESE FACTORS INCLUDE RESULTS OF CURRENT OR PENDING RESEARCH AND DEVELOPMENT ACTIVITIES, ACTIONS BY THE FDA AND OTHER REGULATORY AUTHORITIES, AND THOSE FACTORS DETAILED IN THE COMPANY'S FILINGS WITH THE SECURITIES AND EXCHANGE COMMISSION SUCH AS 10K, 10Q AND 8K REPORTS. # # #

Exhibit 99.2 Contact: Robert J. Hugin Brian P. Gill President and COO Senior Director PR/IR Celgene Corporation Celgene Corporation (908) 673-9102 (908) 673-9530 CELGENE ANNOUNCES PRICING OF COMMON STOCK OFFERING SUMMIT, NJ - (NOVEMBER 3, 2006) - CELGENE CORPORATION (NASDAQ: CELG), announced the pricing of its public offering of 20,000,000 shares of its common stock at a public offering price of $51.60 per share. The gross proceeds of the offering will be $1.032 billion. This offering of the shares of Celgene common stock may be made only by means of a prospectus. A copy of the prospectus relating to the securities can be obtained from: J.P. Morgan Securities Inc., 277 Park Avenue, New York, New York 10172 and Merrill Lynch & Co., 4 World Financial Center, New York, New York 10080. This communication shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. ABOUT CELGENE Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the Company's website at www.celgene.com. THIS RELEASE CONTAINS CERTAIN FORWARD-LOOKING STATEMENTS WHICH INVOLVE KNOWN AND UNKNOWN RISKS, DELAYS, UNCERTAINTIES AND OTHER FACTORS NOT UNDER THE COMPANY'S CONTROL, WHICH MAY CAUSE ACTUAL RESULTS, PERFORMANCE OR ACHIEVEMENTS OF THE COMPANY TO BE MATERIALLY DIFFERENT FROM THE RESULTS, PERFORMANCE OR OTHER EXPECTATIONS IMPLIED BY THESE FORWARD-LOOKING STATEMENTS. THESE FACTORS INCLUDE RESULTS OF CURRENT OR PENDING RESEARCH AND DEVELOPMENT ACTIVITIES, ACTIONS BY THE FDA AND OTHER REGULATORY AUTHORITIES, AND THOSE FACTORS DETAILED IN THE COMPANY'S FILINGS WITH THE SECURITIES AND EXCHANGE COMMISSION SUCH AS 10K, 10Q AND 8K REPORTS. # # #


